Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Nucletron bolsters cancer radiation position with Isodose merger

This article was originally published in Clinica

Executive Summary

Dutch cancer radiation therapy firms Nucletron and Isodose Control are set to merge and become the leader in the global brachytherapy market. According to Nucletron this complementary deal will merge Nucletron with the number three firm in the sector. Ede-based Isodose was founded by Eric van’t Hooft in 2003 – its products include the Flexitron remote brachytherapy delivery system and Flexiplan brachytherapy planning system. Mr van’t Hooft, who also founded Veenendaal-based Nucletron in 1975, will become a member of the executive management team at the newly-merged Nucletron and will hold the title of founder. Financial terms of the deal were not disclosed.

Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

MT042917

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel